Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total value of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The stock was sold at an average price of $31.07, for a total value of $71,181.37.

Pharvaris Price Performance

Shares of PHVS traded up $0.17 during trading hours on Tuesday, hitting $35.48. The stock had a trading volume of 249,398 shares, compared to its average volume of 317,631. The firm has a market capitalization of $2.32 billion, a PE ratio of -11.62 and a beta of -2.31. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $36.93. The stock has a fifty day moving average price of $33.79 and a 200 day moving average price of $30.17.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, analysts anticipate that Pharvaris N.V. will post -3.08 EPS for the current fiscal year.

Analysts Set New Price Targets

PHVS has been the topic of several recent research reports. Guggenheim increased their price target on shares of Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research report on Friday. HSBC raised Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Wells Fargo & Company started coverage on Pharvaris in a research report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $51.08.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Pharvaris, signaling continued confidence in the company’s long-term opportunity. The analyst still forecasts a shift to profitability by FY2029, with projected earnings of $3.09 per share. HC Wainwright Predicts Pharvaris’ Q4 Earnings
• Neutral Sentiment: HC Wainwright issued quarterly estimates of losses per share of $0.92 for Q3 2026, $0.98 for Q4 2026, $0.99 for Q1 2027, $0.89 for Q2 2027 and $0.77 for Q3 2027. The firm projects a FY2026 loss of $3.41 per share and a FY2027 loss of $3.30 per share, indicating that Pharvaris is expected to remain unprofitable in the near term.
• Negative Sentiment: The analyst lowered its FY2026 loss estimate from $2.98 to $3.41 per share and cut its FY2027 loss estimate from $2.41 to $3.30. Longer-term forecasts also weakened: FY2028 estimates moved from a $0.02 loss to a $0.56 loss, while FY2029 earnings were reduced from $3.23 to $3.09 per share. These revisions suggest higher anticipated expenses or a slower path to profitability and could limit upside despite the continued Buy rating.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently made changes to their positions in the business. venBio Partners LLC acquired a new position in Pharvaris in the second quarter valued at $160,569,809,000. Deerfield Management Company L.P. grew its holdings in shares of Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares in the last quarter. Commodore Capital LP grew its holdings in shares of Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. Paradigm Biocapital Advisors LP raised its position in Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after buying an additional 772,583 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in Pharvaris in the 3rd quarter valued at approximately $43,282,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.